Article
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2013
Mellema Wouter W, Dingemans Anne-Marie C, Thunnissen Erik, Snijders Peter J F, Derks Jules, Heideman Daniëlle A M, Van Suylen Robertjan, Smit Egbert F
Abstract excerpt
BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with dismal outcome for non-small-cell lung cancer (NSCLC) patients. The role of KRAS mutation as a predictor of response to chemotherapy for patients with metastatic NSCLC is poorly understood. METHODS: From a retrospective database of two university hospitals, all patients with advanced, nonsquamous NSCLC treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.